HC Wainwright Predicts MediWound FY2029 Earnings

MediWound Ltd. (NASDAQ:MDWD) – Investment analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of MediWound in a research note issued on Thursday, March 20th. HC Wainwright analyst S. Ramakanth expects that the biopharmaceutical company will post earnings of $2.45 per share for the year. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.66) per share.

Other equities research analysts have also issued reports about the company. StockNews.com upgraded MediWound to a “sell” rating in a report on Friday. Craig Hallum initiated coverage on MediWound in a report on Friday, February 28th. They issued a “buy” rating and a $39.00 target price for the company.

MediWound Price Performance

Shares of MediWound stock opened at $16.27 on Friday. The firm has a market cap of $175.60 million, a price-to-earnings ratio of -5.61 and a beta of 0.82. MediWound has a 52-week low of $12.78 and a 52-week high of $24.00. The stock has a 50-day simple moving average of $18.17 and a 200-day simple moving average of $17.59.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.23. The business had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.79 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the previous year, the company earned ($0.19) EPS.

Institutional Investors Weigh In On MediWound

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. R Squared Ltd acquired a new stake in MediWound in the 4th quarter worth approximately $32,000. Russell Investments Group Ltd. increased its position in MediWound by 154.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 1,162 shares during the period. MetLife Investment Management LLC bought a new position in MediWound in the 3rd quarter worth approximately $89,000. Bank of America Corp DE increased its position in MediWound by 38.0% in the 4th quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 2,178 shares during the period. Finally, Rhumbline Advisers increased its position in MediWound by 7.3% in the 4th quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 739 shares during the period. 46.83% of the stock is currently owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.